Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric ADHD (US)
ADHD is a common pediatric neurodevelopmental disorder, with diagnosis rates supported by increased awareness and routine screening; however, symptoms often persist into adulthood. Longacting psychostimulants have dominated treatment for decades due to rapid onset, strong efficacy, and convenient oncedaily dosing. Nevertheless, their classification as controlled substances, along with concerns related to misuse, administrative burden, and recent supply disruptions, increasingly influences prescribing behavior. As a result, nonstimulant therapies are gaining importance, particularly for patients with tolerability concerns or a preference for noncontrolled treatment options, despite perceptions of lower efficacy relative to stimulants. Overall, the market will remain stimulantled while becoming more diversified, with treatment selection driven by safety, convenience, access, and individual patient needs.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric ADHD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed patients?
- How have branded drugs (e.g., Vyvanse, Qelbree) been integrated into the treatment algorithm, and what is their source of business?
- What percentage of pediatric ADHD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of pediatric ADHD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Content highlights
Real-world data: U.S. pharmacy and medical claims data
Key drugs covered: Adhansia XR, Adzenys XR-ODT, Intuniv, Jornay PM, Qelbree, Strattera, Vyvanse, Xelstrym, Zenzedi, generics
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
Key analysis
- Brand / therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
